Compare iShares Self-Driving EV and Tech (IDRV) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Self-Driving EV and Tech vs TransMedics Group Inc — how do they compare? iShares Self-Driving EV and Tech trades at $36.06, while TransMedics Group Inc trades at $70.87 (market cap $2.57B). The key difference: iShares Self-Driving EV and Tech is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| IDRV | TMDX | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $45.48 | $150.42 |
52-Week Low | $32.13 | $61.99 |
Market Cap | — | $2.57B |
Enterprise Value | — | $2.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDRV trades at $35.67, down 1.22% for the day, with a bearish technical signal from moving averages and oscillators. The stock faces resistance near $36 and support at $35. Recent news highlights strong global EV sales growth and China's expanding market ambitions, though U.S. adoption lags. A dividend of $0.30 is scheduled for June 2026.
The outlook for IDRV is clouded by technical weakness and competitive pressures, but long-term EV adoption trends offer potential. Key risks include regulatory hurdles and market volatility. Investors should weigh the bearish signals against sector growth catalysts.
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
